Bolt Biotherapeutics, Inc. (BOLT) income statement
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.10−0.55 (-9.73%)
Close on Nov 18, 2026Market cap $9.82MP/E –Yield –
Bolt Biotherapeutics, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -1098.0%
- Net margin
- -1034.4%
- Return on equity, FY2025
- -79.7%
Financial strength
- Current ratio
- 2.05
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 165.7%
Valuation
- P/E ratio
- –
- Price to sales
- 3.88
- Price to book
- 1.15
- Dividend yield
- –
See a number that looks wrong?